SOPHiA GENETICS, known for its cloud-native healthcare technology, continues its mission to democratize data-driven medicine through its AI-powered SOPHiA DDM™ Platform, supporting cancer and ...

By increasing the availability of MSK-ACCESS® powered with SOPHiA DDM™, SOPHiA GENETICS and AstraZeneca aim to understand further how liquid biopsy testing can complement solid tissue testing and, in ...

By increasing the availability of MSK-ACCESS® powered with SOPHiA DDM™, SOPHiA GENETICS and AstraZeneca aim to understand further how liquid biopsy testing can complement solid tissue testing ...

and genetic disorders, where understanding the specific genomic characteristics of each patient may enable more targeted therapies. Additionally, MSK-ACCESS ® powered with SOPHiA DDM TM ...

The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster. Biopharma ...

"With SOPHiA DDM™, we have been able to confidently identify genetic rearrangements that provide critical insights into the complexity of cancer," said Dr. Jessica Van Ziffle, Associate ...

SOPHiA DDM ™ analyzes thousands of new oncology and rare disease cases daily, continuously refining and improving its AI capabilities. Unlike AI models trained in controlled environments, SOPHiA ...

BOSTON, MA and ROLLE, Switzerland, March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic ...

SOPHiA GENETICS do not believe that these revenues ... It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights ...